Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00461955 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation

Study acronym: Expansion
StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Trial status: Recruiting to Completed Site details revisedv4 Show 1 more changeShow less
    • Site details revised
  3. Start date: May 2007 to Aug 2007 Enrollment target: 14 to 13 · Primary completion date: Sep 2008 · Completion date: May 2009 to Aug 2009 · 3 morev3 Show 6 more changesShow less
    • Enrollment target: 14 to 13
    • Primary completion date: Sep 2008
    • Completion date: May 2009 to Aug 2009
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints revised (4)
    • Study arms: 0 to 1

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Not Yet Recruiting to Recruiting Site details revisedv2 Show 1 more changeShow less
    • Site details revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hematopoietic reconstitution defined by a neutrophils number \> 500/mm3 at day 7 after injection of ex vivo amplified graft and by a platelets number \> 20000/mm3, at day 15 after the injection of ex vivo amplified graft, without transfusion.
Trial Details
NCT Number NCT00461955
Lead Sponsor University Hospital, Bordeaux
Conditions Multiple Myeloma
Enrollment 13 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov